Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Long-term Use of Infliximab in Severe Juvenile Dermatomyositis - 12 Years of Follow-up.
Acta Dermatovenerol Croat
November 2024
Prof. Marija Jelušić, MD, PhD, Department of Paediatrics, University of Zagreb, School of Medicine, Division of Clinical Immunology, Rheumatology and Allergology, Centre of Reference for Paediatric and Adolescent Rheumatology of Ministry of Health of the Republic Croatia, University Hospital Centre Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia;
Juvenile dermatomyositis with emphasized vasculopathy is rare, but the most severe form of the disease, with a poor prognosis with relapsing and chronic course or, in some cases, lethal outcome. We present a case of a 19-year-old Caucasian female, who developed severe acute juvenile dermatomyositis with emphasized multisystem vasculopathy, including retinal vasculopathy and maculopathy (cotton-wool spots, retinal hemorrhages, macular edema) at the age of 8. Due to no response to standard treatment protocols and rapid worsening of clinical symptoms and laboratory findings, a TNF inhibitor (infliximab) was introduced after the third week of treatment resulting in complete normalisation of muscle enzyme levels and complete resolution of eye changes within the next 2 weeks with a gradual general recovery.
View Article and Find Full Text PDFEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
A likely case of chronic graft-versus-host disease polymyositis affecting respiratory and truncal muscles - a comprehensive diagnostic approach.
Blood Cell Ther
November 2024
Department of Haematology, Singapore General Hospital, Singapore.
Article Synopsis
- Polymyositis is a rare complication of graft-versus-host disease (GvHD) that primarily affects muscle tissues, particularly in patients after stem cell transplants.
- A 23-year-old male with chronic myeloid leukemia experienced severe muscle weakness and respiratory issues six months post-transplant, leading to the diagnosis of GvHD polymyositis through various tests including muscle biopsies and imaging.
- The patient responded positively to treatments like corticosteroids and extracorporeal photopheresis, underscoring the need for prompt diagnosis and a collaborative approach to managing this condition.
Atypical presentation of anti-small ubiquitin-like modifier 1 and melanoma differentiation-associated gene 5 antibody positive dermatomyositis presenting with significant inflammatory myopathy on biopsy and normal creatine kinase levels: A case report.
SAGE Open Med Case Rep
November 2024
Department of Rheumatology, University of California San Francisco Fresno, Fresno, CA, USA.
Article Synopsis
- Idiopathic inflammatory myopathies involve chronic inflammation of skeletal muscle and include subtypes like dermatomyositis, polymyositis, and necrotizing autoimmune myopathies.
- A 19-year-old female case highlights an atypical presentation of dermatomyositis, where she exhibited classic symptoms but had normal creatinine kinase levels and severe inflammatory myopathy on biopsy.
- This case illustrates the need to rely on comprehensive clinical evaluations, as laboratory results may not always align with a patient's physical presentation.
Increased risk of pulmonary embolism in patients with dermatomyositis/polymyositis, a retrospective cohort study from Israel.
Thromb Res
December 2024
Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer 5262100, Israel.
Background: Despite the well-established association between chronic inflammatory conditions and pulmonary embolism(PE), previous investigations of the relationship between Dermatomyositis(DM) and Polymyositis(PM) with PE were scarce and have been subject to significant limitations, including small sample sizes and failure to account for potential confounders.
Objectives: To investigate the correlation between DM/PM and PE, as well as assessing the impact of serologic status, myonecrosis, and inflammation markers on this relationship.
Methods: In this large, nationwide population-based study, we used the Clalit Health Services medical database and extracted all DM/PM patients who were first diagnosed between 1 January 2002 to 31 December 2018 and compared them with age and gender matched controls in a ratio of 1:5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!